CHRS Stock — Coherus Oncology Inc.: Cash, EV, Pipeline

What they do

We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.77

Market cap

$119.0M

Cash

$82.9M

Enterprise value

$36.1M

Balance sheet

Cash	$82.9M
Debt	$0.0M
Net cash	$82.9M
Enterprise value	$36.1M
Basic shares	154.5M shares
Fully diluted shares	229.6M shares
Fully diluted market cap	$176.8M
Cash per share	$0.54
Quarterly burn	$62.1M
Cash runway	1.3 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

154.5M

Pre-funded warrants

0.0M

Options

29.2M

RSUs

0.2M

Warrants

18.3M

Converts

25.0M

Conv preferred

0.0M

ESPP reserve

2.4M

FDSO

229.6M

Cap table as of 2025-12-31.

Price history

Loading CHRS daily closes…

Loading price history…

Next catalyst

casdozokitug · Est. Nov 7, 2026 · half midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 7, 2026 Now half midpoint	casdozokitug randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L unresectable HCC · NCT06679985	Phase 2	1L unresectable HCC	2H 2026
Nov 11 - Dec 23 in 4d	CHS-114	Phase 1	Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma	—
Oct 13 - Nov 24 in 11 mo	Casdozokitug	Phase 2	Hepatocellular Carcinoma	—
Feb 9 - Mar 22 in 15 mo	STC-15 monotherapy	Phase 2	Solid Tumor; Sarcoma; Leiomyosarcoma	—
Feb 12 - Mar 25 in 15 mo	CHS-114	Phase 1	Metastatic Solid Tumor; Advanced Solid Tumor	—
Jul 11 - Aug 22 in 20 mo	CHS-1000	Phase 1	Advanced or Metastatic Solid Tumors	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

LOQTORZI

Approved · Active Modality: anti-PD-1 monoclonal antibody

Aliases toripalimab-tpzi

Target PD-1

Partnerships Junshi Biosciences (co-development and commercialization, US/Canada); Apotex (Canada license)

Indications

nasopharyngeal carcinoma (NPC) (Approved)

Status note FDA-approved and marketed; launched in US January 2024; Health Canada approval October 2025.

Casdozokitug

Phase 2 · Active Modality: antagonist monoclonal antibody

Aliases CHS-388, SRF388

Target IL-27

Indications

hepatocellular carcinoma (Phase 2)
lung cancer (Phase 2)
renal cell carcinoma (Phase 2)

Status note Mid-stage clinical candidate; FDA orphan drug designation; global rights held by Coherus; no discontinuation disclosed.

Tagmokitug

Phase 1 · Active Modality: afucosylated IgG1 monoclonal antibody

Aliases CHS-114, SRF114

Target CCR8

Partnerships Vaccinex (worldwide exclusive license); Janssen (clinical supply agreement for pasritamig combination)

Indications

head and neck squamous cell carcinoma (Phase 1)
metastatic castration-resistant prostate cancer (with pasritamig) (Phase 1)

Status note Phase 1 enrolling in HNSCC with and without LOQTORZI; Phase 1b with pasritamig in mCRPC; global rights held by Coherus; no discontinuation disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Toripalimab
Lead indication	Nasopharyngeal Cancer Recurrent
Lead phase	Phase 4
Active trials	5
Collaborator trials	9

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06679985	Phase 2	Active, not recruiting	Sponsor	CHRS	—	Hepatocellular Carcinoma	2H 2026 Est. Nov 7, 2026 · half midpoint
NCT05635643	Phase 1	Active, not recruiting	Sponsor	CHRS	—	Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma	—
NCT06657144	Phase 1	Recruiting	Sponsor	CHRS	—	Metastatic Solid Tumor; Advanced Solid Tumor	—
NCT06389526	Phase 1	Not yet recruiting	Sponsor	CHRS	—	Advanced or Metastatic Solid Tumors	—
NCT06457503	Not disclosed	Recruiting	Sponsor	CHRS	—	Nasopharyngeal Cancer Recurrent	—
NCT05479045	Phase 2	Not yet recruiting	Collaborator	Georgetown University	—	Ovarian Cancer Stage IV; Ovarian Cancer Stage III; Ovarian Cancer Stage 3	—
NCT06975293	Phase 2	Recruiting	Collaborator	STORM Therapeutics LTD	—	Solid Tumor; Sarcoma; Leiomyosarcoma	—
NCT07214987	Phase 2	Recruiting	Collaborator	Massachusetts General Hospital	—	Squamous Cell Carcinoma; Head and Neck Cancer Squamous Cell Carcinoma; Head and Neck Cancer	—
NCT06940180	Phase 2	Recruiting	Collaborator	Dana-Farber Cancer Institute	—	Sinonasal Cancer; Paranasal Sinus Neoplasms; Squamous Cell Carcinoma	—
NCT07281716	Phase 2	Recruiting	Collaborator	Dan Feng	—	Metastatic Microsatellite Stable Colorectal Carcinoma	—
NCT07277322	Phase 2	Recruiting	Collaborator	Dan Feng	—	Metastatic Colorectal Cancer; Liver Metastases	—
NCT07423078	Phase 2	Recruiting	Collaborator	Matthew Spector	—	Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (; Locally Advanced Laryngeal Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 9 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 14 active trials for Coherus Oncology, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	10,366	no change	0.00%	2026-08-14
Tang Capital Partners	0	-1,886,748	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CHRS — Coherus Oncology Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

CHRS — Coherus Oncology Inc.